The Lancet position paper "Psychopharmacology in children and adolescents: unmet needs and opportunities" has now been released.
The document addresses the unmet needs and opportunities, including the perspectives of clinicians and researchers from the European College of Neuropsychopharmacology – Child and Adolescent Network, alongside those of experts by lived experience from national and international associations, via a survey involving 644 participants from 13 countries, and of regulators, through representation from the European Medicines Agency.
Furthermore, the paper discusses the evidence base for medications currently used for mental disorders in
children and adolescents, medications in the pipeline, opportunities in the development of novel medications, crucial
priorities for the conduct of future clinical studies, challenges and opportunities in terms of the regulatory and
legislative framework, and innovations in the way research is conducted, reported, and promoted.
EUFAMI's own Board Member and Treasurer, and also President of the Swedish Schizophrenia Association, Dr. Asa Konradsson-Geuken, has contributed to this paper as an expert assistant professor in Neuropsychopharmacology at the Uppsala University in Sweden.
You can access the full article here (384.04 Ko) "pdf".
